Novo Nordisk A/S: Notice for the Annual General Meeting of Novo Nordisk A/S Bagsværd, Denmark, 20 February 2026 – The Annual General Meeting will be held on: Thursday 26 March 2026 at 14:00 (CET) The Annual General Meeting will be held as a combined physical and virtual meeting. Accordingly, shareholders can choose between participating in person at Bella Center, Center Boulevard 5, entrance 6, 2300 Copenhagen S, Denmark, or virtually by PC or smartphone/tablet. We encourage shareholders to exercise their rights by submitting proxies or votes by correspondence in advance of the Annual Gen...
Hermès International: Release on compensation of Executive Chairmen as of 16 February 2026 PRESS RELEASE Paris, 16 February 20266 p.m EXECUTIVE CHAIRMEN COMPENSATION In accordance with the Afep-Medef Corporate Governance Code (art. 27.1) HERMES INTERNATIONAL discloses information on all potential or acquired elements of its Executive Chairmen compensation, immediately following the Board meeting having established these elements. Principles The compensation elements detailed below, relating to the 2025 financial year, are all in line with the Executive Chairmen compensation policy appr...
Hermès International : Communiqué sur la rémunération des gérants du 16 février 2026 COMMUNIQUÉ Paris, le 16 février 202618h00 REMUNERATION DES GÉRANTS Conformément au Code de gouvernement d’entreprise Afep-Medef (art 27.1) HERMES INTERNATIONAL rend publics tous les éléments de rémunération potentiels ou acquis des gérants après la réunion du conseil les ayant arrêtés. Principes Les éléments de rémunération détaillés ci-dessous, relatifs à l’exercice 2025, sont tous conformes à la politique de rémunération des gérants approuvée par l’Assemblée générale du 30 avril 2025 et présentée dan...
Novo Nordisk A/S - share repurchase programme Bagsværd, Denmark, 16 February 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026. Under the programme initiated 4 February 2026, Novo Nordisk will rep...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.